Tsunenori Kondo

Adachi, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 515 publications

Editorial Comment to Preoperative Tumor Shape Irregularity Is Associated With Pathological Upstaging to pT3 in Clinical T1 Renal Cell Carcinoma Treated With Partial or Radical Nephrectomy.

Editorial Comment to Preoperative Tumor Shape Irregularity Is Associated With Pathological Upstaging to pT3 in Clinical T1 Renal Cell Carcinoma Treated With Partial or Radical Nephrectomy.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: August 07, 2026

Gingival Fibroblast-Driven Osteoimmunology via the IL-33-ILC2-IL-13 Axis.

Gingival Fibroblast-Driven Osteoimmunology via the IL-33-ILC2-IL-13 Axis.

Journal: Journal of dental research

Published: June 22, 2026

Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab for Patients Aged 80 Years and Older With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.

Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab for Patients Aged 80 Years and Older With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.

Journal: Anticancer research

Published: May 18, 2026

Editorial Comment to Real-World Effectiveness and Safety of Pembrolizumab-Lenvatinib Versus Axitinib-Based Regimens in Metastatic Clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Study.

Editorial Comment to Real-World Effectiveness and Safety of Pembrolizumab-Lenvatinib Versus Axitinib-Based Regimens in Metastatic Clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: April 18, 2026

Standardizing Upper Abdominal Fascial Terminology: A Transdisciplinary Expert Consensus From the Japanese Society for Endoscopic Surgery.

Standardizing Upper Abdominal Fascial Terminology: A Transdisciplinary Expert Consensus From the Japanese Society for Endoscopic Surgery.

Journal: Asian journal of endoscopic surgery

Published: April 06, 2026

Editorial Comment to the Impact of the Relevant Factors as High-Complexity Tumors in Robot-Assisted Partial Nephrectomy.

Editorial Comment to the Impact of the Relevant Factors as High-Complexity Tumors in Robot-Assisted Partial Nephrectomy.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: March 26, 2026

Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker.

Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker.

Journal: Targeted oncology

Published: February 28, 2026

Comparison of clinical outcomes of cabozantinib plus nivolumab and lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma.

Comparison of clinical outcomes of cabozantinib plus nivolumab and lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma.

Journal: International urology and nephrology

Published: February 28, 2026

A Minimum 3-Year Follow-Up of Nivolumab-Plus-Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J-ENCORE Study.

A Minimum 3-Year Follow-Up of Nivolumab-Plus-Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J-ENCORE Study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: January 18, 2026

Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma.

Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma.

Journal: Japanese journal of clinical oncology

Published: January 11, 2026

Midterm Outcomes of Combination Therapy With Immune Checkpoint Inhibitors and VEGFR-TKIs in Real-World Patients With Advanced Renal Cell Carcinoma.

Midterm Outcomes of Combination Therapy With Immune Checkpoint Inhibitors and VEGFR-TKIs in Real-World Patients With Advanced Renal Cell Carcinoma.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: November 25, 2025

Clinical evaluation of medical and surgical complete responses in metastatic renal cell carcinoma treated with immune checkpoint inhibitor combination therapy.

Clinical evaluation of medical and surgical complete responses in metastatic renal cell carcinoma treated with immune checkpoint inhibitor combination therapy.

Journal: International journal of clinical oncology

Published: November 04, 2025

Showing 1-12 of 515

Last Updated: 09/26/2026